Ombipepimut-s is under clinical development by Sumitomo Pharma and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ombipepimut-s’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ombipepimut-s overview

Ombipepimut-s ((DSP-7888 (elatipepimut-S (DSR-124888) in combination with adegrapepimut-S (DSR-131617)) is under development for the treatment of solid tumors including acute myeloid leukemia (AML), melanoma, non-small cell lung cancer (NSCLC), colorectal adenomas in familial adenomatous polyposis, head and neck squamous cell carcinoma, astrocytoma urothelial neoplasms, ovarian cancer, pancreatic cancer, sarcomas, metastatic renal cell carcinoma,recurrent  head and neck cancer squamous cell carcinoma, metastatic transitional cell cancer (urothelial cell cancer), metastatic melanoma, metastatic hepatocellular carcinoma, colorectal cancer, adenocarcinoma of the gastroesophageal junction, gastric cancer, cervical cancer, peritoneal cancer, ovarian cancer, fallopian tube cancer. DSP-7888 is a vaccine containing peptides, adegramotide, and nelatimotide, that induces WT1-specific cytotoxic T lymphocytes (CTLs) and helper T cells. It is administered intradermally or subcutaneously. The vaccine candidate targets WT1 (Wilms tumor gene 1). It was also under development for hematologic malignancies, acute myeloid leukemia (AML), recurrent glioblastoma multiforme (GBM), pediatric relapsed or refractory high grade gliomas including diffuse intrinsic pontine glioma, glioblastoma, grade III or IV gliomas, myelodysplastic syndrome (MDS) and soft tissue sarcoma.

Sumitomo Pharma overview

Sumitomo Pharma, a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. It also offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Dainippon has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Osaka, Japan.

For a complete picture of Ombipepimut-s’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.